Stay updated with breaking news from Acne Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track -- Dermata continues discussions with potential botulinum toxin partners for DMT410 -- Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESSWIRE / May 15, 202...
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical ...
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20, 2023 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company&q...